CLOROX CO DE
For the period ended Mar 31, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 30, 2024
CLX$106.60+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
| Nine months ended | ||
|---|---|---|
| 3/31/2024 | 3/31/2023 | |
| Operating activities: | ||
| Net earnings (losses) | $71 | $(20) |
| Adjustments to reconcile net earnings (losses) to net cash provided by operations: | ||
| Depreciation and amortization | 176 | 174 |
| Stock-based compensation | 55 | 60 |
| Deferred income taxes | (126) | (122) |
| Loss on divestiture | 238 | — |
| Pension settlement charge | 171 | — |
| Goodwill, trademark and other asset impairments | — | 445 |
| Other | 18 | 34 |
| Changes in: | ||
| Receivables, net | (16) | (1) |
| Inventories, net | 20 | 13 |
| Prepaid expenses and other current assets | 12 | (15) |
| Accounts payable and accrued liabilities | (120) | 78 |
| Operating lease right-of-use assets and liabilities, net | — | 2 |
| Income taxes payable / prepaid | (144) | 80 |
| Net cash provided by operations | 355 | 728 |
| Investing activities: | ||
| Capital expenditures | (131) | (144) |
| Proceeds from divestiture, net of cash divested | 17 | — |
| Other | 20 | 2 |
| Net cash used for investing activities | (94) | (142) |
| Financing activities: | ||
| Notes and loans payable, net | 61 | (99) |
| Cash dividends paid to Clorox stockholders | (446) | (437) |
| Issuance of common stock for employee stock plans and other | 3 | 10 |
| Net cash used for financing activities | (382) | (526) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (26) | — |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (147) | 60 |
| Cash, cash equivalents and restricted cash: | ||
| Beginning of period | 368 | 186 |
| End of period | $221 | $246 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.